Brand-name drug · GLP-1 receptor agonist
Foundayo (orforglipron)
From the FDA label, read Published by PepVault
Foundayo is orforglipron, a once-daily tablet from Eli Lilly that can be taken with or without food.
FDA approved it, together with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity, or with overweight and at least one weight-related condition.
- Active ingredient
- Orforglipron
- Maker
- Eli Lilly
- Class
- GLP-1 receptor agonist
- FDA application
- NDA 220934, first approved 2026
What FDA approved it for
Weight is its one approved use. The label advises against taking it with another GLP-1 medicine.
From the label: 2.1 Recommended Dosage and Administration; 1 Indications and Usage.
How it is supplied
| Form | Doses |
|---|---|
| Tablet | 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, 17.2 mg |
From the label: 3 Dosage Forms and Strengths.
The label’s dosing schedule
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Foundayo, once a day
| Dose | When, on the label |
|---|---|
| 0.8 mg a day | At least 30 days |
| 2.5 mg a day | At least 30 days |
| 5.5 mg a day | At least 30 days |
| 9 mg a day | After at least 30 days, by response and tolerability |
| 14.5 mg a day | After at least 30 days, by response and tolerability |
| 17.2 mg a day | The maximum |
The first three steps, 0.8 mg, 2.5 mg and 5.5 mg, each last at least 30 days and are there to lower the chance of stomach side effects. Beyond 5.5 mg, each higher level follows only if the response and tolerability call for it.
From the label: 2.1 Recommended Dosage and Administration.
How it’s taken
One tablet a day, swallowed whole, with no breaking, crushing or chewing and never more than one in a day. Unlike the semaglutide tablets, the label sets no empty-stomach rule: food is fine.
Some other medicines change how much orforglipron the body keeps. With a strong CYP3A4 inhibitor the label caps Foundayo at 9 mg a day, and it asks to avoid strong CYP3A4 inducers altogether.
From the label: 2.1 Recommended Dosage and Administration; 2.2 Dosage Modification for Concomitant Use with CYP3A4 Inhibitors and CYP3A4 Inducers.

If a dose is missed
A missed Foundayo tablet is taken as soon as it’s remembered, without doubling the next one.
After 7 or more missed days in a row, the label restarts the climb at a lower dose.
From the label: 2.3 Recommendations Regarding Missed Dose.
Storage
Foundayo needs no fridge: it is stored at room temperature, 68°F to 77°F, with short spells between 59°F and 86°F allowed.
From the label: 16.2 Storage and Handling.
Side effects and warnings
| Reaction | Placebo | 5.5 mg | 9 mg | 17.2 mg |
|---|---|---|---|---|
| Nausea | 10 | 26 | 34 | 35 |
| Constipation | 9 | 20 | 27 | 24 |
| Diarrhea | 11 | 21 | 23 | 25 |
| Vomiting | 4 | 13 | 21 | 24 |
| Dyspepsia | 4 | 12 | 16 | 13 |
| Abdominal pain | 7 | 13 | 14 | 14 |
| Headache | 7 | 8 | 9 | 9 |
| Abdominal distension | 3 | 7 | 9 | 8 |
| Fatigue | 4 | 6 | 7 | 9 |
| Eructation (burping) | 1 | 6 | 8 | 8 |
Nausea led, reported by 35% on 17.2 mg against 10% on placebo; constipation, diarrhea and vomiting each reached about a quarter of people on the higher doses.
The boxed warning
The other warnings
Its other warnings: pancreatitis, severe stomach effects, kidney injury from fluid loss, low blood sugar, allergic reactions, diabetic eye changes in type 2 diabetes, gallbladder disease and aspiration under anesthesia.
From the label: 6.1 Clinical Trials Experience; Boxed Warning; 5 Warnings and Precautions.
What else we have on orforglipron
Orforglipron on PepVault
The trials, in plain English
- Orforglipron 36 mg: 11.2% weight loss at 72 weeks in ATTAIN-1
- Orforglipron: 9.6% weight loss at 72 weeks in ATTAIN-2
- Orforglipron: heart events no worse than insulin in ACHIEVE-4
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3
- Orforglipron: food lowered drug exposure by 17.6% to 23.7%
Brand against brand
Questions about Foundayo
What is the starting dose of Foundayo?
The label starts at 0.8 mg once a day for at least 30 days, then 2.5 mg, then 5.5 mg, each for at least 30 days. A prescriber sets the schedule.
What is the maximum dose of Foundayo?
17.2 mg once a day. With a strong CYP3A4 inhibitor, the label’s cap is 9 mg a day.
Does Foundayo have to be taken on an empty stomach?
No. The label says to take it once a day with or without food, swallowed whole.
What if I miss a Foundayo dose?
Take it as soon as possible and don’t double the next one. After 7 or more missed days in a row, the label restarts the climb at a lower dose.
What is Foundayo approved for?
Reducing excess weight and keeping it off, with diet and activity, in adults with obesity or with overweight and a weight-related condition.
Sources
- FOUNDAYO (orforglipron) tablets, for oral use, FDA label on DailyMed (version 10, published Aug 13, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 220934 (Foundayo, the tablets; application first approved 2026)
PepVault is not affiliated with Eli Lilly. Foundayo is a trademark of its owner.